Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.53 |
| ▸ | SRC | P12931 | 7/20 | 0.53 |
| ▸ | ZAP70 | P43403 | 7/20 | 0.53 |
| ▸ | CDK2 | P24941 | 4/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.40 |
| ▸ | STK16 | O75716 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CLK3 | P49761 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.39 |
| ▸ | MERTK | Q12866 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633882 | 0.92 | SYK (0.47) | SYKSRCZAP70CHEK1AXL | |
| SCHEMBL1571587 | 0.86 | CYP1A2 (0.44) | SYKSRCZAP70CDK2CHEK1 | |
| SCHEMBL1632924 | 0.84 | PRKCZ (0.39) | SYKCHEK1AXLTYRO3MERTK | |
| SCHEMBL1633716 | 0.83 | PRKCZ (0.38) | SYKCDK2CHEK1CDK4JAK2 | |
| SCHEMBL1633274 | 0.82 | PRKCQ (0.45) | SYKSRCZAP70CHEK1AXL | |
| SCHEMBL13363268 | 0.81 | PRKCZ (0.39) | SYKCHEK1AXLTYRO3MERTK | |
| SCHEMBL13336215 | 0.80 | BRAF (0.41) | SYKCHEK1JAK2JAK1JAK3 | |
| SCHEMBL13335980 | 0.80 | SYK (0.44) | SYKGSK3BCHEK1TYRO3JAK2 | |
| SCHEMBL13336156 | 0.80 | BRAF (0.41) | SYKAXLTYRO3JAK2JAK1 | |
| SCHEMBL1635190 | 0.80 | SYK (0.49) | SYKSRCZAP70CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | SYK 4204/4885SRC 1131/4885ZAP70 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.